ֱ

Vascepa Generics; Apple Watch Captures STEMI; COVID-19 Hit 1 in 3 Cath Labs' Staff

— Recent developments of interest in cardiovascular medicine

MedpageToday
Electrocardiogram on top and bottom of image with CardioBreak in the center.

came a step closer, with an appeals court affirming Amarin's patents are invalid. (Endpoints News)

But Amarin announced a of the fish-oil derived drug for and other respiratory infection complications in older adults with heart disease. (Yahoo! News)

Putting the in different spots on the chest and torso captured the equivalent of nine ECG lead positions that yielded 84% sensitivity and 100% specificity for ST-segment elevation MI versus a standard ECG. (JAMA Cardiology)

Almost one in three cath labs had , according to a professional society survey of program directors and interventional cardiologists. (Catheterization & Cardiovascular Interventions)

A pacemaker with closed loop stimulation substantially in the BIOSync CLS study. (Pharmacy Times)

Boston Scientific's paclitaxel-eluting for peripheral artery disease scored a new technology add-on payment from CMS as of October 2020 that will increase reimbursement 65% for in-hospital use, the company announced.

Two prominent from the same research team were retracted from the Journal of the American College of Cardiology (JACC), both pertaining to , after discovery of research misconduct that undermined the findings.

Cardiac MRI on 22 college athletes showed after a mild or asymptomatic course of COVID-19, which would have been missed by ECG and strain echo, researchers reported in a non-peer-reviewed preprint on medRxiv.

In another preprint on medRxiv, a meta-analysis affirmed renin-angiotensin-aldosterone system drugs appear , actually finding a significant 27% reduced mortality risk.

The U.S. is among the many countries on commitments to reduce premature mortality from CVD and other chronic noncommunicable diseases, according to a report in The Lancet.

Offering for CV risk assessment pulled in typically underrepresented groups: older, female, and African-American people and those from lower-income areas. (JACC)

Sonosite's point-of-care ultrasound system got FDA clearance for . (Diagnostic Imaging)

One cardiologist's story of how she came to is on Thrive Global.